Trimetazidine

What is the drug thought to do in the body?

Changes in metabolism and the way energy is used in the body has been seen in MND. In many cases, these changes cause the body to use more energy than normal and have been linked to faster disease progression. Trimetazidine is a partial fatty acid oxidation inhibitor, which is already used to correct changes in metabolism in angina. In MND, it is thought trimetazidine could slow disease progression by reducing heightened metabolism and oxidative stress.

Phase 2 - MetFlex

Current status: Awaiting topline results 

Primary objective: To investigate the safety of trimetazidine

The Phase 2a open-label, single-arm trial is investigating the safety and tolerability of trimetazidine for the treatment of MND. The trial recruited 36 participants across Australia and the Netherlands. You can find out more about the trial here.

Last updated: 21/08/2024